Lv21
170 积分 2024-09-06 加入
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
6小时前
已完结
Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and its Major Metabolites: Implications for Dose Adjustment
5天前
已完结
Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors
5天前
已完结
Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
20天前
已完结
BTLA and HVEM: Emerging players in the tumor microenvironment and cancer progression
20天前
已完结
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator
21天前
已完结
Proceedings of the 2020 Classic Examples in Toxicologic Pathology XXVII
1个月前
已完结
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
3个月前
已完结
Adagrasib-induced photodistributed hyperpigmentation: two case reports and pathogenetic hypothesis*
3个月前
已关闭
A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET)
3个月前
已完结
皖公网安备34019202002308
